Cannabidiol for the Treatment of Refractory Seizures
Provided are methods of treating refractory seizures in a human subject, e.g., a child, that include administering an effective amount of cannabidiol (CBD), e.g., in a transdermal gel.
1 . A method of treating refractory seizures in a human subject suffering from an autism spectrum disorder (ASD), the method comprising:
administering an effective amount of cannabidiol (CBD) to the human subject in need thereof to treat the refractory seizures.
2 . The method of claim 1 , wherein the human subject is between 3 and 18 years old and is diagnosed with ASD.
3 . The method of claim 1 or 2 , wherein the subject has a refractory epilepsy.
4 . The method according to any of the preceding claims, wherein the refractory seizures treated are selected from the group consisting of focal impaired awareness seizures (FIAS), generalized tonic-clonic seizures (GTCS), or focal to bilateral tonic-clonic seizures (FBTCS).
5 . The method according to any of the preceding claims, wherein the CBD is administered transdermally.
6 . The method according to any of the preceding claims, wherein the effective amount of CBD ranges from about 250 mg to about 1000 mg total daily.
7 . The method of claim 6 , wherein the effective amount of CBD is 250 mg total daily.
8 . The method of claim 6 , wherein the effective amount of CBD is 500 mg total daily.
9 . The method of claim 6 , wherein the effective amount of CBD is 750 mg total daily.
10 . The method of claim 6 , wherein the effective amount of CBD is 1000 mg total daily.
11 . The method according to any of the preceding claims, wherein the CBD is administered in a single daily dose.
12 . The method according to any of claims 1 - 10 , wherein the CBD is administered in two daily doses.
13 . The method according to any of the preceding claims, wherein the treatment includes an improvement in sleep-related impairment.
14 . The method of claim 13 , wherein an improvement in sleep-related impairment includes improvements in sleep quality, sleep onset, total sleep, initiating and maintain sleep, sleep wake transition, or disorders of arousal and nightmares.
15 . The method according to any of the preceding claims, wherein the CBD is a synthetic CBD.
16 . The method according to any of the preceding claims, wherein the CBD is a pure CBD.
17 . The method according to any of claim 1 - 14 or 16 , wherein the CBD is botanically derived.
19 . The method according to any of the preceding claims, wherein the cannabidiol is (−)-cannabidiol.
20 . The method according to any of the preceding claims, wherein the CBD is formulated as a gel.
21 . The method of claim 20 , wherein the CBD is formulated as a permeation-enhanced gel.
22 . The method according to any of the preceding claims, wherein, upon beginning administering the effective amount of CBD, circadian rhythm is maintained or improved.
23 . The method according to any of the preceding claims, wherein administering the effective amount of CBD does not become addictive.
24 . The method according to any of the preceding claims, wherein, upon beginning administering the effective amount of CBD, the human subject experiences no excessive somnolence.
25 . A method of treating refractory seizures in a human subject suffering from autism spectrum disorder (ASD) and sleep disturbance the method comprising: administering an effective amount of cannabidiol (CBD) to the human subject to treat the refractory seizures and sleep disturbance.
26 . The method of claim 25 , wherein the human subject is between 3 and 18 years old, and is diagnosed with ASD.
27 . The method of claim 25 or 26 , wherein the refractory seizures treated are selected from the group consisting of focal impaired awareness seizures (FIAS), generalized tonic-clonic seizures (GTCS), or focal to bilateral tonic-clonic seizures (FBTCS).
28 . The method of any one of claims 25 to 27 , wherein the human subject is also suffering from developmental and epileptic encephalopathies (DEE).
29 . A method of treating refractory seizures in a child suffering from developmental and epileptic encephalopathies (DEE), the method comprising:
administering an effective amount of cannabidiol (CBD) to the child, wherein the refractory seizures are treated in response to administration of CBD.